HYDROchlorothiazide to PROTECT Polycystic Kidney Disease Patients and Improve Their Quality of Life
Status:
Not yet recruiting
Trial end date:
2028-12-01
Target enrollment:
Participant gender:
Summary
Autosomal dominant polycystic kidney disease (ADPKD) is characterized by progressive
formation of renal cysts which ultimately lead to a loss of renal function.
Tolvaptan (a V2R antagonist) is currently the only effective treatment for preserving renal
function in ADPKD. However, side-effects such as polyuria limit its tolerability and thereby
the therapeutic potential. This study will test whether co-administration with
hydochlorothiazide can improve V2RA efficacy (slowing kidney function decline) and
tolerability (quality of life) in ADPKD. Approximately 300 patients will be enrolled.